Aktie A086900 MEDY-TOX INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Medy-Tox Inc.

Aktien

A086900

KR7086900008

A086900

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 28.06.2024 		% 5 Tage % 1. Jan.
151’500 KRW -4.54% Intraday Chart für Medy-Tox Inc. +10.66% -37.14%
16.05. Medy-Tox Inc. meldet Ergebnis für das erste Quartal zum 31. März 2024 CI
21.03. Medy-Tox Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
South Korean Shares Close Marginally Lower on North Korea's Artillery Shells Firing
Medy Tox Establishes Subsidiary Luvantas in California
Medytox, Inc. Announces the Formation of Luvantas Subsidiary
Medytox, Inc. Announces Executive Appointments in Luvantas, Inc
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
AEON Biopharma, Inc. completed the acquisition of Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.
Medy-Tox Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Medy-Tox Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
AEON Biopharma, Inc. entered into a definitive business combination agreement to acquire Priveterra Acquisition Corp. from Priveterra Sponsor, LLC, Empyrean Capital Overseas Master Fund, Ltd., managed by Empyrean Capital Partners, LP, Medy-Tox Inc., Daewoong pharmaceutical Co.,Ltd, Strathspey Crown LLC and others in a reverse merger transaction.
Medy-Tox Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on August 17, 2022.
Medy-Tox Inc.'s Equity Buyback announced on August 17, 2022, has closed with 41,771 shares, representing 0.70% for KRW 5,084.38 million.
Medy-Tox Inc.(KOSDAQ:A086900) dropped from FTSE All-World Index
Medy-Tox Inc. announces an Equity Buyback for 41,771 shares.
Medy-Tox Inc. authorizes a Buyback Plan.
Medy-Tox Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Tranche Update on Medy-Tox Inc.'s Equity Buyback Plan announced on June 7, 2022.
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A086900 Aktie
  4. Nachrichten Medy-Tox Inc.
  5. Andere Sprachen